The DREAMM-7 trial showed tolerability and safety profiles consistent with those observed for individual therapies. Credit: ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), announced that Nanoviricides CEO Dr Anil Diwan joined ...
Shares fall flat; Origin’s revenue drops; Mayne Pharma shares decline as investors bet on its takeover deal being dead; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback